Hyperparathyroidism
MONDO:0001741Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.
Also known as: hyperparathyroidism
84 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Could a vitamin d pill help kids with kidney disease avoid dialysis?
Disease control TerminatedThis phase 3 trial compares two oral vitamin D therapies—Hectorol (doxercalciferol) and Rocaltrol (calcitriol)—in children aged 5 to 18 with chronic kidney disease stages 3 or 4 who have high parathyroid hormone levels but are not yet on dialysis. The main goal is to see if Hecto…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Kidney drug trial for infants and toddlers halted early
Disease control TerminatedThis study tested a liquid medicine called paricalcitol in children aged 0 to 9 years with severe kidney failure who are on dialysis. The goal was to see if it safely lowers high parathyroid hormone levels, a common complication. The trial was stopped early after enrolling only 2…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New vitamin d pill aims to tame parathyroid glands in dialysis patients
Disease control TerminatedThis phase 2 study tested a weekly extended-release capsule of calcifediol (CTAP101) in 44 adults with chronic kidney disease on hemodialysis who also had vitamin D insufficiency and secondary hyperparathyroidism. The goal was to see if the drug could raise vitamin D levels and l…
Phase: PHASE2 • Sponsor: OPKO Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Old arthritis drug tested against rare tumor syndrome – but trial stalls
Disease control TerminatedThis study tested leflunomide, a drug used for rheumatoid arthritis, in 3 adults with MEN1 syndrome—a genetic condition that raises the risk of multiple tumors. The goal was to see if 6 months of daily leflunomide could shrink or stabilize tumors. However, the trial was terminate…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gut bugs linked to bone loss in parathyroid disease
Knowledge-focused TerminatedThis study looked at whether the types of bacteria in the gut can predict bone loss in people with primary hyperparathyroidism, a condition where the parathyroid glands produce too much hormone. Researchers planned to analyze gut bacteria and immune system markers in 25 patients …
Sponsor: Centre Hospitalier Universitaire Vaudois • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC